Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030
Description
Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030
The Central Lab Market size was estimated at USD 3.11 billion in 2023 and expected to reach USD 3.38 billion in 2024, at a CAGR 9.25% to reach USD 5.78 billion by 2030.
A central lab operates as a core facility providing high-quality and standardized testing services across various clinical trial sites globally. These labs are pivotal for ensuring data integrity, consistency, and reliability, a prerequisite for effective clinical research and development. The increasing need for specialized testing services, the surge in clinical trials worldwide, and the pharmaceutical industry's emphasis on outsourcing to enhance efficiency and focus on core competencies are expanding the need for central labs. However, the sector faces restraints such as high operational costs, regulatory complexities, and the challenge of maintaining standardization across global operations. Central labs leverage technological advancements, establish strategic partnerships, and enhance their geographical presence to provide localized services while maintaining international standards to address these restraints. The expansion of biomarker services, personalized medicine, and the integration of artificial intelligence for predictive analysis are setting a trajectory for central labs in the evolving clinical research landscape.
Regional Insights
In the Americas, the central lab market demonstrates robust growth, fueled by a surge in clinical trial activities and a robust infrastructure for research and development. The rising importance of advanced diagnostics and biomarker development has accelerated the investment for central labs in the Americas. The APAC region stands out for its rapid expansion, driven by increasing investments in healthcare, a growing focus on regulatory compliance, and strategic global partnerships facilitating technology transfer and capability enhancements. A shift toward precision medicine lays the foundation for a dynamic and interconnected global central lab ecosystem for APAC. EMEA showcases an advanced market with stringent regulatory frameworks and a high degree of harmonization in laboratory practices. This region benefits from a history of pharmaceutical research, a highly skilled workforce, and a focus on innovation, particularly in personalized medicine.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Central Lab Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rise in the number of clinical trials and complexity of drug development activities
- Government initiatives promoting precision medicine worldwide
- Market Restraints
- High cost of set-up and maintenance of central labs
- Market Opportunities
- Technological integrations and smart features in central labs
- Investments for establishment and expansion of central labs
- Market Challenges
- Operational limitations and standardization complexities
- Market Segmentation Analysis
- Services Type: Preference for central labs for long-term storage of biological samples under controlled conditions for specific management
- Phase: Integral role of the central labs for the execution of the entire clinical trial process
- End-use: Need to facilitate seamless clinical trials, ensuring data integrity and operational excellence for pharmaceutical companies
- Therapeutic Area: Comprehensive diagnostic and prognostic testing for oncology and infectious diseases therapeutic areas
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Central Lab Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Central Lab Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Medpace Central Labs Expand Singapore Facility
Medpace Central Laboratories expanded its Singapore facility to enhance service delivery to its sponsors. It was established as a primary lab for clinical research within the Asia-Pacific in 2009 and has been operating diligently out of Singapore since 2014. The fully-owned Singapore lab and other Medpace laboratories ensure consistent results by adhering to global operating procedures and leveraging a unified laboratory information management system. The facility is equipped to support various therapeutic areas with advanced testing capabilities.
Vial Announces Collaborative Alliance with MLM Medical Labs for offering Central Laboratory Solutions
Vial joined forces with MLM Medical Labs to enhance its central laboratory offerings by incorporating MLM’s comprehensive solutions, such as study setup management, sample analysis, and its unique MLM Kit building system, which streamlines sample collection through tailor-made kits, barcode tracking, and color-coded labels. Additionally, MLM enhances sample management and clinical data access through its proprietary MLM Sample Storage System and MLM-Online, while its collaboration with TruLab, Inc. ensures meticulous sample tracking and protocol adherence, enriching the clinical trial process for sponsors, CROs, and on-site staff.
Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
Cerba HealthCare acquired CIRION BIOPHARMA RESEARCH INC to enhance its HealthCare's offerings under the Cerba Research brand in clinical and IVD trials across a wide range of medical fields. CIRION excels in developing biosimilars/biologics and offers specialized services such as PKPD and immunogenicity testing.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Central Lab Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Central Lab Market, highlighting leading vendors and their innovative profiles. These include ACM Medical Laboratory, Inc., Almac Group, Cerba HealthCare, CROMSOURCE by ClinChoice, Cryoport, Inc., Eurofins Scientific SE, Exagen Inc., Frontage Laboratories, Inc., GBA Group, GCCL Co., Ltd., ICON PLC, InterlabCorp, Intertek Group PLC, IQVIA Inc., LabConnect, Inc., Laboratory Corporation of America Holdings, Lambda Therapeutic Research Ltd., Lotus Labs Pvt. Ltd. by Teva Pharmaceutical Industries Ltd., MDS Pharma Services, Medicover AB, Medpace, Inc., MLM Medical Labs GmbH, Novotech Health Holdings, Pace Analytical Services, LLC, Precision Medicine Group, LLC, Quest Diagnostics Incorporated, REPROCELL Inc., SGS S.A., Shanghai Clinical Research Center, SMS Pharmaceuticals Ltd., Sonic Healthcare International, Syngene International Limited, Thermo Fisher Scientific Inc., Unilabs AB, Versiti, Inc., and WuXi AppTec.
Market Segmentation & Coverage
This research report categorizes the Central Lab Market to forecast the revenues and analyze trends in each of the following sub-markets:- Service Type
- Anatomic Pathology/Histology
- Biomarker Services
- Genetic Services
- Microbiology Services
- Special Chemistry Services
- Specimen Management & Storage
- Phase
- Phase 1
- Phase 2
- Phase 3
- Therapeutic Area
- Autoimmune Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Oncology
- End-use
- Academic & Research Institutes
- Biotechnology Companies
- Pathology & Diagnostic Lab
- Pharmaceutical Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rise in the number of clinical trials and complexity of drug development activities
- 5.1.1.2. Government initiatives promoting precision medicine worldwide
- 5.1.2. Restraints
- 5.1.2.1. High cost of set-up and maintenance of central labs
- 5.1.3. Opportunities
- 5.1.3.1. Technological integrations and smart features in central labs
- 5.1.3.2. Investments for establishment and expansion of central labs
- 5.1.4. Challenges
- 5.1.4.1. Operational limitations and standardization complexities
- 5.2. Market Segmentation Analysis
- 5.2.1. Services Type: Preference for central labs for long-term storage of biological samples under controlled conditions for specific management
- 5.2.2. Phase: Integral role of the central labs for the execution of the entire clinical trial process
- 5.2.3. End-use: Need to facilitate seamless clinical trials, ensuring data integrity and operational excellence for pharmaceutical companies
- 5.2.4. Therapeutic Area: Comprehensive diagnostic and prognostic testing for oncology and infectious diseases therapeutic areas
- 5.3. Market Trend Analysis
- 5.3.1. Leveraging advanced integration of data analytics for enhanced central lab efficiency across Americas
- 5.3.2. Significant surge in clinical trials and burgeoning government initiatives for investments and expansions of central lab services across APAC
- 5.3.3. Stringent regulations concerning biological sample collection for clinical trials and exploration of strategic collaborations between medical laboratories in the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Central Lab Market, by Service Type
- 6.1. Introduction
- 6.2. Anatomic Pathology/Histology
- 6.3. Biomarker Services
- 6.4. Genetic Services
- 6.5. Microbiology Services
- 6.6. Special Chemistry Services
- 6.7. Specimen Management & Storage
- 7. Central Lab Market, by Phase
- 7.1. Introduction
- 7.2. Phase 1
- 7.3. Phase 2
- 7.4. Phase 3
- 8. Central Lab Market, by Therapeutic Area
- 8.1. Introduction
- 8.2. Autoimmune Diseases
- 8.3. Cardiovascular Diseases
- 8.4. Infectious Diseases
- 8.5. Neurology
- 8.6. Oncology
- 9. Central Lab Market, by End-use
- 9.1. Introduction
- 9.2. Academic & Research Institutes
- 9.3. Biotechnology Companies
- 9.4. Pathology & Diagnostic Lab
- 9.5. Pharmaceutical Companies
- 10. Americas Central Lab Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Central Lab Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Central Lab Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Medpace Central Labs Expand Singapore Facility
- 13.3.2. Vial Announces Collaborative Alliance with MLM Medical Labs for offering Central Laboratory Solutions
- 13.3.3. Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
- 13.3.4. Cleveland Clinic and LabConnect announce Strategic Alliance for Improved Patient Care
- 13.3.5. Versiti Acquires Indiana-based Quantigen for Accelerating Pace of Innovation for Preclinical Research Services
- 13.3.6. Labor Dr. Wisplinghoff and Labconnect Announce Strategic Alliance - Expanding Global Central Laboratory Services to Accelerate the Development of Medicines
- 13.3.7. IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
- 13.3.8. Cerba Research Offers a Customized, Innovative Approach to its Partners in the Laboratory Services
- 13.3.9. Medpace Central Labs Expand Histology & Anatomic Pathology Services
- 13.3.10. Thermo Fisher to invest USD 59 Million for Clinical Research Lab Expansion in the U.S.
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
